Back to Search
Start Over
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)
- Source :
- Rheumatology (Oxford, England), r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Publication Year :
- 2021
- Publisher :
- OXFORD UNIV PRESS, 2021.
-
Abstract
- Introduction Endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i) are beneficial in pulmonary arterial hypertension (PAH) and digital ulcers (DU) and prevent from DU recurrences. Our study aimed to determine the difference in the incidence rate of PAH and scleroderma renal crisis (SRC) in patients with SSc and DU (SSc-DU) under ERAs/PDE5i or without treatment. Methods We conducted a retrospective cohort study including SSc-DU patients from the Spanish Scleroderma Registry (RESCLE). The primary outcome was the incidence rate of PAH and SRC in patients under ERAs/PDE5i or not. Results Some 544 patients out of 1817 (29.9%) in the RESCLE database had DU, 221 (40.6%) under ERAs/PDE5i and 323 (59.4%) not. The incidence rate (95% CI) difference between patients under treatment or not under did not reach statistical significance in PAH [−0.1 (−4.8, 4.69), P = 0.988] or in SRC [0.7 (−2.2, 3.7), P = 0.620]. However, the time from the first DU to the diagnosis of SRC was delayed in treated patients [mean (s.d.) 7.6 (5.8) years vs 2.9 (5.3); P = 0.021]. The dcSSc subset was more prevalent in the treatment group (36 vs 26%; P = 0.018), along with anti-topoisomerase I antibodies (34 vs 18%; P Conclusion There was no difference in the incidence rate of PAH and SRC between groups. However, treatment with ERAs and/or PDE5i appeared to delay the occurrence of SRC.
- Subjects :
- Endothelin Receptor Antagonists
Male
medicine.medical_specialty
Scleroderma Renal Crisis
030204 cardiovascular system & hematology
Systemic scleroderma
Gastroenterology
Scleroderma
endothelin antagonist receptors, phosphodiesterase-5 inhibitors, prevention, pulmonary arterial hypertension, scleroderma renal crisis, treatment
Fingers
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
Statistical significance
Skin Ulcer
medicine
Humans
Pharmacology (medical)
Registries
skin and connective tissue diseases
030203 arthritis & rheumatology
Pulmonary Arterial Hypertension
Scleroderma, Systemic
integumentary system
business.industry
Incidence
Antagonist
Retrospective cohort study
Acute Kidney Injury
Middle Aged
Phosphodiesterase 5 Inhibitors
medicine.disease
Treatment Outcome
Spain
cGMP-specific phosphodiesterase type 5
Blood Vessels
Female
Endothelin receptor
business
Subjects
Details
- ISSN :
- 14620324
- Database :
- OpenAIRE
- Journal :
- Rheumatology (Oxford, England), r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Accession number :
- edsair.doi.dedup.....e388d761b4f7a7db9f19fa291f027498